PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Peripheral Vasopressors in Septic Shock: Faster Start, Very Low-Certainty Evidence

★ Editor's Picknorepinephrinephenylephrinevasopressorsperipheral intravenous cathetercentral venous catheterseptic shockextravasationsystematic reviewmeta-analysisobservational cohortscritical caresepsis managementhemodynamics Critical Care / ICU

Background Information

Peripheral vasopressors offer a rapid, safe start in septic shock.

Central venous catheters (CVCs) for vasopressors delay hemodynamic stabilization and pose procedural risks. Peripheral vasopressor delivery reduced initiation time by 1.4-2.1 hours without compromising safety, showing low extravasation rates (0%-5.5%). Peripheral vasopressors may be a viable initial option in septic shock, but evidence is of very low certainty due to heterogeneity and observational data. Peripheral vasopressors can swiftly initiate treatment in septic shock, potentially avoiding CVC-related risks.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Nayel A, Alqurain A, Muhammad A, Hakami A, Ahmed R, Al-Atawi S, Abdeltawab A, Aljohani M, Ariahi G, Metwaly A, Syoty M, Alhuqbani A, Albalushi A, Al-Hazmy B

Citation: Nayel A, Alqurain A, Muhammad A, et al. Safety and efficiency of peripheral versus central line vasopressor administration in septic shock: a systematic review and meta-analysis. Journal of critical care medicine (Universitatea de Medicina si Farmacie din Targu-Mures). 2026;12(4):487-497. doi:10.62838/jccm-2026-0036

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.